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Abstract
Background: Many patients with chronic diseases use complementary therapies, often provided by their physicians. In
Germany, several physician-provided complementary therapies have been reimbursed by health insurance companies as
part of health benefit programs. In most of these therapies, the patient has a predominantly passive role. In eurythmy
therapy, however, patients actively exercise specific movements with the hands, the feet or the whole body. The purpose
of this study was to describe clinical outcomes in patients practising eurythmy therapy exercises for chronic diseases.
Methods: In conjunction with a health benefit program, 419 outpatients from 94 medical practices in Germany, referred
to 118 eurythmy therapists, participated in a prospective cohort study. Main outcomes were disease severity (Disease
and Symptom Scores, physicians' and patients' assessment on numerical rating scales 0–10) and quality of life (adults: SF-
36, children aged 8–16: KINDL, children 1–7: KITA). Disease Score was documented after 0, 6 and 12 months, other
outcomes after 0, 3, 6, 12, 18, 24, and (SF-36 and Symptom Score) 48 months.
Results:  Most common indications were mental disorders (31.7% of patients; primarily depression, fatigue, and
childhood emotional disorder) and musculoskeletal diseases (23.4%). Median disease duration at baseline was 3.0 years
(interquartile range 1.0–8.5). Median number of eurythmy therapy sessions was 12 (interquartile range 10–19), median
therapy duration was 119 days (84–188).
All outcomes improved significantly between baseline and all subsequent follow-ups (exceptions: KITA Psychosoma in
first three months and KINDL). Improvements from baseline to 12 months were: Disease Score from mean (standard
deviation) 6.65 (1.81) to 3.19 (2.27) (p < 0.001), Symptom Score from 5.95 (1.75) to 3.49 (2.12) (p < 0.001), SF-36 Physical
Component Summary from 43.13 (10.25) to 47.10 (9.78) (p < 0.001), SF-36 Mental Component Summary from 38.31
(11.67) to 45.01 (11.76) (p < 0.001), KITA Psychosoma from 69.53 (15.45) to 77.21 (13.60) (p = 0.001), and KITA Daily
Life from 59.23 (21.78) to 68.14 (18.52) (p = 0.001). All these improvements were maintained until the last follow-up.
Improvements were similar in patients not using diagnosis-related adjunctive therapies within the first six study months.
Adverse reactions to eurythmy therapy occurred in 3.1% (13/419) of patients. No patient stopped eurythmy therapy due
to adverse reactions.
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Conclusion: Patients practising eurythmy therapy exercises had long-term improvement of chronic disease symptoms
and quality of life. Although the pre-post design of the present study does not allow for conclusions about comparative
effectiveness, study findings suggest that eurythmy therapy can be useful for patients motivated for this therapy.
Background
In the developed world the most frequent reason for peo-
ple to seek health care is a chronic disease [1]. Chronic dis-
eases are the most common cause of disease burden
worldwide, are often associated with comorbidity, and are
rarely completely cured [1]. Strategies to improve the out-
come of chronic diseases include drug regimens,
enhanced healthcare provision, and patient self-manage-
ment programs [2-4]. Many patients with chronic disease
also use complementary therapies [5,6], often provided
by their physicians. In Germany, several physician-pro-
vided complementary therapies have been reimbursed by
health insurance companies as part of special health ben-
efit programs ("Modellvorhaben") [7-10]. In most of
these complementary therapies the physician is the active
person, directly treating (e.g. giving acupuncture) or pre-
scribing therapy (e.g. homoeopathic medications), while
the patient has a predominantly passive role. Anthropo-
sophic medicine (AM, a complementary system of medi-
cine founded by Rudolf Steiner and Ita Wegman [11]),
includes two interventions that require the patient to
engage in active exercises: AM art and eurythmy therapy.
Eurythmy therapy (EYT, Greek: eurythmy = "harmonious
rhythm") is an exercise therapy involving cognitive, emo-
tional, and volitional elements [12]. EYT is prescribed by
AM physicians and provided by EYT therapists in individ-
ual or small group sessions during which patients are
instructed to perform specific movements with the hands,
the feet or the whole body. EYT movements are related to
the sounds of vowels and consonants, to music intervals
or to soul gestures, e.g. sympathy-antipathy. For each
patient one or several movements are selected, depending
on the patient's disease, his constitution, and on the EYT
therapist's observation of the patient's movement pattern.
This selection is based on a core set of principles, prescrib-
ing specific EYT movements for specific diseases, constitu-
tional types, and movement patterns [13,14].
EYT sessions usually last 45 min; between therapy ses-
sions patients practice EYT exercises daily [14]. An EYT
therapy cycle usually consists of 12–15 sessions. EYT can
be used as monotherapy or combined with other AM ther-
apies. Qualification as an EYT therapist requires 5 1/2
years of training according to an international, standard-
ised curriculum. EYT is presently provided by approxi-
mately 1,550 therapists in 31 countries worldwide (A.
Jaschke, International Coordination AM, personal com-
munication, February 2007). Half of EYT therapists work
in Germany or Switzerland. In these two countries EYT
costs ca. 40 Euro per session and is covered by many
health insurance companies. In other countries costs vary
and are not covered by health insurance.
EYT is believed to have both general effects (e.g. improv-
ing breathing patterns and posture, strengthening muscle
tone, enhancing physical vitality [15]) and disease-spe-
cific effects [14]. Observational studies suggest that EYT
and other AM therapies can be useful for a variety of clin-
ical conditions [12,16-25]. However, all these studies
were monocentric, all but one [12] evaluated multimodal
AM therapy including EYT in only a proportion of the
patients, and all but three studies [18-20] had a sample
size of less than 25 AM patients. Here we present a multi-
centre long-term study of EYT with 419 patients.
Methods
Study design and objective
This is a prospective four-year cohort study in a real-world
medical setting. The study was part of a research project
on the effectiveness and costs of AM therapies in outpa-
tients with chronic disease (Anthroposophic Medicine
Outcomes Study, AMOS) [8,26]. The AMOS project was
initiated by a health insurance company in conjunction
with a health benefit program and included the following
effectiveness issues:
1) Are AM therapies in general associated with clinically
relevant improvements of chronic diseases? (see [8])
2) Are specific AM therapies (such as EYT) associated with
such improvements?
3) If yes: To which extent are these improvements found
in different age, gender, and diagnostic subgroups?
4) How do improvements of specific diagnostic groups
compare to improvements with other interventions?
The issues 2 and 3 were addressed in this EYT analysis, the
objective of which was to study symptoms, quality of life,
adjunctive therapies, health service use, adverse reactions,
and therapy satisfaction in outpatients with chronic dis-
eases receiving EYT under routine clinical conditions. EYT
was evaluated as a therapy package, including physician-
and therapist-patient interactions.BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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Setting, participants and therapy
All physicians certified by the Physicians' Association for
Anthroposophical Medicine in Germany and working in
an office-based practice or outpatient clinic in Germany
were invited to participate in the study. The participating
physicians were instructed to enrol consecutive patients
fulfilling eligibility criteria. Inclusion criteria were (1) out-
patients aged 1–75 years, (2) referral to EYT for any indi-
cation (main diagnosis). Exclusion criteria were (1)
previous EYT for main diagnosis, (2) ongoing EYT.
Participating EYT therapists were certified by the
Eurythmy Therapy Association of Germany. EYT was
administered at the discretion of the physicians and EYT
therapists.
Clinical outcomes
￿ Disease severity was assessed on numerical rating scales
[27] from 0 („not present“) to 10 („worst possible“): Dis-
ease Score (physician's global assessment of severity of
main diagnosis, documented in patients enrolled up to 30
Sep 2000); Symptom Score (patients' assessment of one to
six most relevant symptoms present at baseline, docu-
mented in patients enrolled after 1 Jan 1999).
￿ Quality of life was assessed with SF-36® Physical and
Mental Component Summary Measures, the eight SF-36
subscales, and the SF-36 Health Change item [28] for
adults; with KINDL® 40-item version, Summary Score and
four subscales [29] for children 8–16 years; and with KITA
Psychosoma and Daily Life subscales [30] for children 1–
7 years.
Disease Score was documented after 0, 6 and 12 months,
other clinical outcomes after 0, 3, 6, 12, 18, 24, and
(Symptom Score and SF-36) 48 months.
Other outcomes
￿ Adjunctive therapy and health service use in the pre-
study year was documented at study enrolment, use in the
first study year was documented after six and 12 months,
and use in the second study year was documented after 18
and 24 months. Items were: medication (additional doc-
umentation after three months), physician and dentist
visits, paraclinical investigations, inpatient hospital and
rehabilitation treatment, surgeries, physiotherapy, ergot-
herapy, psychotherapy, Heilpraktiker (non-medical prac-
titioner) visits, and sick leave.
￿ Use of diagnosis-related adjunctive therapies within the
first six study months was analysed in patients with a
main diagnosis of mental, respiratory or musculoskeletal
diseases, or headache disorders. Diagnosis-related thera-
pies were any of the following therapies, if used for at least
one day per month: Mental diseases: psychotherapy (in
children ergotherapy or play therapy), antiepileptic, psyc-
holeptic, analeptic, and anti-addiction drugs (ATC-Index
N03A, N05–06, N07B); Respiratory diseases: relevant
drugs (H02, J01–02, J04–05, J07A, L03, R01, R03, R06–
07) or surgery; Musculoskeletal diseases: immunosup-
pressive, musculoskeletal, analgesic and antidepressant
drugs (L04, M01–05, M09, N02A-B, N06A), physiother-
apy or relevant surgery; Headache disorders: analgesics,
antimigraine drugs and antidepressants (C04AX01,
C07AA05, C07AB02, C08CA06, C08DA01, N02,
N03AG01, N06A, N07CA03).
￿ Therapy ratings were documented after six and 12
months: Patient rating of therapy outcome, patient satis-
faction with therapy, EYT effectiveness rating by patient
and physician.
￿ Adverse drug or therapy reactions were documented dur-
ing the first 24 study months: cause, intensity (mild/mod-
erate/severe = no/some/complete impairment of normal
daily activities); Serious Adverse Events (physician docu-
mentation).
Data collection
All data were documented with questionnaires sent in
sealed envelopes to the study office. Physicians docu-
mented eligibility criteria; therapists documented EYT
administration; all other items were documented by
patients (by caregivers of children < 17 years) unless oth-
erwise stated. Patient responses were not made available
to physicians. Physicians were compensated €40 per
included and fully documented patient, while patients
received no compensation.
Data were entered twice by two different persons into
Microsoft® Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University Berlin,
and was conducted according to the Helsinki Declaration
and the International Conference on Harmonisation
Good Clinical Practice guidelines. Written informed con-
sent was obtained from all patients before enrolment.
Data analysis
Data analysis (SPSS®  13.0.1, StatXact®  5.0.3) was per-
formed on all patients fulfilling eligibility criteria. For
continuous data the Wilcoxon Signed-Rank test was used
for paired samples and the Mann-Whitney U-test for inde-
pendent samples; median differences with 95% confi-
dence intervals (95%-CI) were estimated according to
Hodges and Lehmann [31]. For binominal data McNemar
test and Fisher's exact test were used. All tests were two-BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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tailed. Significance criteria were p < 0.05 and 95%-CI not
including 0. Pre-post effect sizes were calculated as Stand-
ardised Response Mean (= mean change score divided by
the standard deviation of the change score) and were clas-
sified as small (0.20–0.49), medium (0.50–0.79), and
large (≥ 0.80) [32]. Unless otherwise stated, therapies and
health services were analysed in patients enrolled after 1
Jan 1999 with at least three out of five follow-ups availa-
ble; for each item and follow-up period, missing values
were replaced by the group mean value. Clinical outcomes
were analysed in patients with evaluable data for each fol-
low-up, without replacement of missing values.
Results
Participating physicians and therapists
101 physicians screened patients referred to EYT. 94 phy-
sicians enrolled patients into the study; these physicians
did not differ significantly from all AM-certified physi-
cians in Germany (n = 362) regarding gender, age,
number of years in practice, and the proportion of pri-
mary care physicians. Patients were treated by 118 EYT
therapists. Comparing these therapists to certified EYT
therapists without study patients (n = 231), no significant
differences were found regarding gender or age. Median
number of years since EYT school graduation was 9.0
years for therapists with study patients and 13.0 years for
therapists without study patients (median difference 2.0
years; 95%-CI 1.0–4.0 years; p = 0.005).
Patient recruitment and follow-up
From 1 July 1998 to 31 March 2001, a total of 498
patients were screened for inclusion. 419 patients fulfilled
all eligibility criteria and were included in the study (Fig-
ure 1). Of the 419 included patients, 36 patients were also
included in a study of depression [33], and 23 patients
were included in a study of low back pain [34]. The last
patient follow-up ensued on 12 April 2005. Included and
not included patients did not differ significantly regarding
age, gender, diagnosis, disease duration, baseline Disease
Score, or baseline Symptom Score.
The total number of patients eligible for screening (i.e.
patients referred to EYT) during the recruitment period
was estimated at approximately 2000 patients. We tested
the hypothesis that the extent of patient selection by each
physician (= the proportion of eligible vs. included
patients) would correlate positively with clinical out-
comes. The proportion was median 2.8 (interquartile
range (IQR) 0.6–7.9, n = 52 physicians). There was a weak
correlation between this proportion and the 0–12 month
improvement of Disease Score (Spearman-Rho 0.19, p =
0.014 n = 168 patients) and no significant correlation
with the improvement of Symptom Score (Spearman-Rho
-0.07, p = 0.311, n = 225 patients).
75.4% (316/419) of patients were enrolled by general
practitioners, 10.0% by paediatricians, 4.5% by internists,
and 10.0% by other specialists. The physicians' setting was
primary care practice (87.8% of patients, n = 368/419),
referral practice (8.6%), and outpatient clinic (3.6%).
97.4% (408/419) of patients returned at least one follow-
up questionnaire. The 12-month questionnaire was
returned by 87.6% of patients; these patients did not dif-
fer significantly from non-respondents (12.4%) regarding
age, gender, diagnosis, disease duration, baseline Disease
Score, and baseline Symptom Score. Corresponding drop-
out analyses for the 24-month follow-up also showed no
differences. The physician follow-up documentation was
available for 84.7% (355/419) of patients after six months
and for 77.2% after 12 months.
Baseline characteristics
Most frequent main diagnoses, classified by ICD-10
(International Classification of Diseases, Tenth Edition),
were F00-F99 Mental Disorders (31.7%, 133/419
patients), M00-M99 Musculoskeletal Diseases (23.4%),
and J00-J99 Respiratory Diseases (7.6%). Most frequent
single diagnoses were back pain/sciatica (8.1%, 34/419
patients), neck-shoulder-arm pain (7.6%), depression
(6.4%), fatigue (6.2%), childhood emotional disorder
(3.8%), headache/migraine (3.3%), and asthma (3.1%).
Median disease duration was 3.0 years (IQR 1.0–8.5); in
97.9% (410/419) of patients disease duration was six
weeks or longer. The patients had median 1.0 (IQR 0.0–
2.0) comorbid diseases. Most common comorbid dis-
eases, classified by ICD-10, were F00-F99 Mental Disor-
ders (14.1%, 91 out of 645 diagnoses), M00-M99
Musculoskeletal Diseases (12.4%), E00-E90 Endocrine,
Nutritional and Metabolic Diseases (9.5%), and I00-I99
Circulatory Diseases (8.5%).
The patients were recruited from 13 of 16 German federal
states. Median age was 38.0 years (IQR 14.0–48.0, mean
34.8 years). Compared to the German population, socio-
demographic items were more favourable for education,
occupation, alcohol, smoking, and overweight; items
were similar for unemployment, low-income, living
alone, severe disability status, sport, underweight; and
were less favourable for work disability pension and sick-
leave (Table 1).
Therapies
EYT administration was documented during the first 24
months after study enrolment. In this period, 93.6%
(392/419) of patients had EYT; 2.9% did not have EYT; for
3.6% EYT documentation is incomplete or inconclusive.
EYT started median 15 (IQR 4–41) days after enrolment.
Median therapy duration was 119 (IQR 84–188) days,BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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Patient recruitment and follow-up Figure 1
Patient recruitment and follow-up. *18-, 24-, and 48-month follow-up questionnaires were not sent to patients enrolled 
before 1 Jan 1999.
No further questionnaires 
sent to 35 patients* 
Not included: n = 79 
x  Patients’ questionnaire missing: n = 33 
x  Patients’ and physicians’ questionnaire 
dated > 30 days apart: n = 29 
x Eligibility  criteria not fulfilled: n = 16 
x  Other reasons: n = 1 
Included in study
n = 419 
Screened for inclusion 
n = 498 
6-month questionnaire 
sent to 419 patients 
Returned
n = 391 (93.3%) 
Returned
n = 390 (93.1%) 
3-month questionnaire 
sent to 419 patients 
Returned
n = 280 (72.9%) 
24-month questionnaire 
sent to 384 patients 
Returned
n = 367 (87.6%) 
12-month questionnaire 
sent to 419 patients 
Not returned 
n = 29 (6.9%) 
Not returned 
n = 28 (6.7%) 
Not returned 
n = 52 (12.4%) 
Not returned 
n = 104 (27.1%) 
Not returned 
n = 79 (20.6%) 
Returned
n = 305 (79.4%) 
18-month questionnaire 
sent to 384 patients 
Returned
n = 242 (63.0%) 
48-month questionnaire 
sent to 384 patients 
Not returned 
n = 142 (37.0%) BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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median number of therapy sessions was 12 (IQR 10–19).
At the last documented EYT session, further EYT sessions
were scheduled for 14% (49/344) of evaluable patients.
During the first six months after study enrolment 72.1%
(302/419) of patients used AM medication and 1.4% (6/
419) had AM art therapy.
Non-AM adjunctive therapies, health services, and sick
leave are listed in Table 2, together with AM medication.
Comparing the pre-study year to the first and second
study year, respectively, the only consistent change over
both years was an increase in psychotherapy by average
one session per patient. In the first study year AM medica-
tion use and the number of physician and dentist visits
increased, and in the second year the number of rehabili-
tation days and non-AM medication use decreased, com-
pared to the pre-study year. The remaining items did not
change significantly.
Use of diagnosis-related adjunctive therapies (see Meth-
ods) within the first six study months was analysed in
patients with a main diagnosis of mental, respiratory or
musculoskeletal diseases, or headache disorders (n =
278). Out of 251 evaluable patients, 63% (n = 157) had
no diagnosis-related adjunctive therapy.
Clinical outcomes
Disease and Symptom Scores (Figure 2), all eleven SF-36
scores (adults, Figure 3), and both KITA subscales (chil-
dren aged 1–7, Figure 4) improved significantly between
baseline and all subsequent follow-ups (except KITA Psy-
chosoma in the first three months). For all these 15 out-
comes, the most pronounced improvement occurred
during the first six months. After 12 months, Disease and
Symptom Scores were improved from baseline in 86.9%
and 83.6% of patients, respectively (Table 3); an improve-
ment of ≥50% of baseline scores was observed in 61.2%
(145/237 evaluable patients) and 46.4% (156/336),
respectively. Disease and Symptom Scores improved sim-
ilarly in male and female adults, in children, and in the
seven most common diagnosis groups. Effect sizes for the
0–12 month comparison were large for Disease and
Symptom Scores (1.34 and 1.04) and small-to-medium
(range 0.41–0.67) for the SF-36 and KITA scores (Table 3).
All these improvements were maintained until the last fol-
low-up.
In children aged 8–16, KINDL Summary Score (Figure 5)
as well as KINDL Psychic and Somatic subscales improved
significantly between baseline and the six-month, 18-
month (except KINDL Somatic subscale), and 24-month
Table 1: Socio-demographic data
Study patients German primary care patients
Items N Percent Percent Source
Female gender 297/419 71% 53% [43]
Age groups 0–19 years 111/419 26% 14% [43]
20–39 years 115/419 27% 27% [43]
40–59 years 150/419 36% 27% [43]
60–75 years 43/419 10% 21% [43]
Adult study patients enrolled after 1 Jan 1999 German population
"Fachhochschule" or university entrance 
qualification
172/280 61% 19% [44]
University degree 76/279 27% 6% [44]
Wage earners 8/280 3% 18% [44]
Unemployed during last 12 months Economically active patients 7/147 5% 10% [44]
Living alone 57/278 20% 21% [44]
Net family income < 900 € per month 33/231 14% 16% [44]
Alcohol use daily (EYT) vs. almost daily 
(Germany)
Male 1/53 2% 28% [45]
Female 7/227 3% 11%
Regular smoking Male 9/53 17% 37% [46]
Female 40/226 18% 28%
Sports activity ≥ 1 hour weekly Age 25–69 116/257 45% 39% [47]
Body mass index < 18.5 (low) Male 4/53 8% 1% [48]
Female 12/223 5% 4%
Body mass index ≥ 25 (overweight) Male 8/53 15% 56% [48]
Female 69/223 31% 39%
Permanent work disability pension 20/279 7% 3% [49]
Severe disability status 24/279 9% 12% [50]
Sick leave days in the last 12 months, mean (SD) Economically active patients 33.0 (68.3) days 17.0 days [51]BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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follow-ups, respectively. KINDL Social and Function sub-
scales did not change significantly during the study.
We performed two post-hoc sensitivity analyses of 0–12
month Disease and Symptom Score outcomes. The first
analysis concerned dropout bias. The main analysis had
comprised all patients with evaluable data at baseline and
12-month follow-up. In the first sensitivity analysis, miss-
ing values after 12 months were replaced with the last
value carried forward, reducing the average 0–12 month
improvements by 19% (3.46→2.78 points) and 4%
(2.46→2.35 points), respectively. The second analysis
concerned the effects of relevant adjunctive therapies, and
was performed on patients with a main diagnosis of men-
tal, respiratory or musculoskeletal diseases or headache
disorders. Restricting this sample to patients not using
diagnosis-related adjunctive therapies during the first six
study months (see Methods), the average Disease and
Symptom Score improvements were increased by 10%
(3.55→3.96 points) and 6% (2.23→2.36 points), respec-
tively.
Other outcomes
At six-month follow-up, patients' average therapy out-
come rating (numeric scale from 0 "no help at all" to 10
"helped very well") was 7.42 (SD 2.29); patient satisfac-
tion with therapy (from 0 "very dissatisfied" to 10 "very
satisfied") was 8.08 (SD 2.19). Patients' EYT effectiveness
rating was positive ("very effective" or "effective") in
86.1% (315/366) of patients, and negative ("less effec-
tive", "ineffective" or "not evaluable") in 13.9%. Physi-
cians' effectiveness rating was positive in 79.3% (264/
333) and negative in 20.7%. Ratings of therapy outcome,
satisfaction, and effectiveness did not differ significantly
between adults and children, or between six- and 12-
month follow-ups.
During the first 24 study months adverse reactions to EYT
occurred in 3.1% (13/419) of patients. Three (0.7%)
patients had adverse reactions of severe intensity (symp-
tom aggravation, inner tension, depressed mood), no
patient stopped EYT due to adverse reactions. One child
had adverse reactions (moderate restlessness) to adjunc-
tive AM massage therapy, which was stopped. Four
patients had adverse reactions to non-AM therapies.
Adverse reactions from AM medications occurred in 5.3%,
(18/337) of users, adverse reactions from non-AM medi-
cation occurred in 12.8% (46/358) of users (p < 0.001).
Nine patients had Serious Adverse Events. Three patients
were acutely hospitalised and six patients died: five from
malignant disease and one patient, hospitalised for severe
depression, from an accident, possibly suicide. None of
these Serious Adverse Events were related to any therapy
or medication.
Discussion
This is the first large study focusing on EYT. We aimed to
obtain information on EYT under routine conditions in
Germany and studied clinical outcomes in outpatients
referred to EYT for chronic diseases. The study was con-
ducted in conjunction with a health insurance program
providing EYT regardless of diagnosis. For this reason, and
because the range and frequency of indications for EYT in
outpatient care was largely unknown prior to the study,
we included patients of all ages with all diagnoses. Most
frequent indications were mental and musculoskeletal
disorders. Following EYT (and adjunctive AM medica-
tion), significant improvements of disease symptoms and
quality of life were observed. The largest improvements
(large effect sizes, half of patients improved by at least
50% of their baseline scores) were observed for the items
which directly measure the conditions treated with EYT,
Table 2: AM medication, non-AM adjunctive therapies, health service use, and sick leave days
Item Pre-study 
year
0–12 months 12–24 months
Mean (SD) Mean (SD) Median difference (95%-
CI) from pre-study year
P value Mean (SD) Median difference (95%-
CI) from pre-study year
P value
AM medicines per day 0.45 (0.80) 0.70 (0.90) 0.24 (0.17 to 0.37) p < 0.001 0.40 (0.71) -0.02 (-0.08 to 0.04) p = 0.505
Non-AM medicines/day 0.65 (0.90) 0.69 (0.94) 0.01 (-0.04 to 0.06) p = 0.628 0.59 (0.88) -0.06 (-0.13 to -0.01) p = 0.032
Physician and dentist visits 18.12 (21.19) 18.82 (16.03) 1.24 (0.19 to 2.50) p = 0.028 18.67 (50.41) -1.43 (-2.50 to 0.00) p = 0.041
Paraclinical investigations 5.70 (6.66) 5.75 (6.77) 0.00 (-0.62 to 0.50) p = 0.737 5.24 (6.71) -0.50 (-1.00 to 0.00) p = 0.093
Hospital days 3.42 (14.72) 2.57 (10.91) -1.10 (-5.00 to 1.46) p = 0.346 2.04 (7.42) -0.04 (-2.32 to 1.18) p = 0.929
Rehabilitation days 2.02 (8.36) 1.76 (7.48) 0.00 (-10.02 to 7.46) p = 0.921 1.55 (6.20) -0.69 (-0.97 to -0.62) p = 0.005
Surgeries 0.19 (0.51) 0.14 (0.41) 0.00 (-0.47 to 0.00) p = 0.323 0.12 (0.38) 0.00 (-0.42 to 0.07) p = 0.909
Physiotherapy and 
ergotherapy sessions
8.92 (17.83) 9.25 (22.80) 1.00 (-2.00 to 4.00) p = 0.425 10.91 (28.35) -1.22 (-4.19 to 1.31) p = 0.379
Psychotherapy sessions 2.64 (12.96) 3.54 (9.42) 3.98 (1.50 to 7.00) p = 0.008 3.56 (10.34) 2.68 (1.67 to 3.67) p < 0.001
Sick leave days* 32.97 (68.26) 34.61 (80.65) 3.50 (-2.00 to 8.00) p = 0.185 29.85 (68.69) 3.18 (-2.18 to 8.00) p = 0.210
Patients with Heilpraktiker 
visit (n + %)**
32/250 (12.8%) 29/250 (11.6%) p = 0.710 27/250 (10.8%) p = 0.511
Patients enrolled after 1 Jan 1999 with at least 3 of 5 follow-ups (n = 339). *Patients engaged in economic activity (n = 128). **Patients with 
complete data for all time periods.BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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i.e. Disease and Symptom Scores. The improvements were
maintained during the four-year follow-up and were not
accompanied by an increase of adjunctive therapies,
except for a small increase in psychotherapy use.
Strengths and limitations
Strengths of this study include a large patient sample, a
long follow-up period, high follow-up rates, and the par-
ticipation of 30% of all AM-certified physicians and EYT
therapists in Germany. The participating physicians and
therapists resembled all eligible physicians/therapists
with respect to socio-demographic characteristics, and
included patients resembled not included, screened
patients regarding baseline characteristics. These features
suggest that the study to a high degree mirrors contempo-
rary EYT practice. Moreover, in the present early phase of
EYT evaluation, the inclusion of all diagnoses is an advan-
tage, offering a comprehensive picture of EYT practice. On
the other hand, it was not feasible to have disease-specific
outcomes for all diagnoses included. Nonetheless, the
larger AMOS project, of which this study is part, included
disease-specific outcomes for major disease groups
[33,34].
Since the study had a long recruitment period, the partic-
ipating physicians were not able to screen and include all
their eligible patients (patients referred to EYT). It was
estimated that physicians enrolled every third patient
referred to EYT. This selection could bias results if physi-
cians were able to predict therapy response and if they
preferentially screened and enrolled such patients for
whom they expected a particularly favourable outcome. In
this case one would expect the degree of selection (= the
proportion of referred vs. enrolled patients) to correlate
positively with clinical outcomes. There was, however,
only a weak correlation with Disease Score (+0.19) and a
no significant correlation with Symptom Score. These
analyses do not suggest that physicians' screening of
patients referred to EYT was affected by selection bias.
A limitation of the study is the absence of a comparison
group receiving another treatment or no therapy. Accord-
ingly, for the observed improvements one has to consider
several other causes apart from EYT: Non-AM adjunctive
therapies cannot explain the improvements of Disease
and Symptom Scores, since the improvements were even
more pronounced in patients not using such therapies
(analysed in patients with mental, respiratory or muscu-
loskeletal disease or headache syndromes, together com-
prising 66% of the study sample). Dropout bias could
explain up to 19% of the 0-12-month improvement of
Disease Score but only 4% of the corresponding Symptom
Score improvement. Natural recovery and regression to
the mean, which could also bias results, will be addressed
in a separate analysis (Hamre et al, submitted for publica-
tion). Other possible confounders are AM medication
(which was used by three-fourth of patients), observation
bias, and psychological factors like patient expectations.
Table 3: Clinical outcomes 0–12 months
Item N 0 months 12 months 0 months vs. 12 months
Mean (SD) Mean (SD) P-value Median difference (95%-CI)* Improved SRM
Disease Score (0–10) 237 6.65 (1.81) 3.19 (2.27) p < 0.001 4.00 (3.50 to 4.00) 87% 1.34
Symptom Score (0–10) 336 5.95 (1.75) 3.49 (2.12) p < 0.001 2.50 (2.25 to 2.75) 84% 1.04
SF-36 scales (0–100)
-Physical Function 270 75.34 (22.74) 83.18 (19.41) p < 0.001 10.00 (7.50 to 10.00) 63% 0.42
-Role Physical 267 42.51 (39.20) 67.79 (37.20) p < 0.001 37.50 (37.50 to 50.00) 55% 0.63
-Role-Emotional 268 47.26 (41.87) 70.58 (38.09) p < 0.001 33.34 (33.30 to 50.00) 49% 0.55
-Social Functioning 272 62.13 (25.75) 75.28 (24.37) p < 0.001 18.75 (12.50 to 25.00) 58% 0.49
-Mental Health 271 54.21 (18.65) 65.05 (19.00) p < 0.001 12.00 (8.00 to 14.00) 71% 0.57
-Bodily Pain 272 55.91 (28.41) 66.93 (27.65) p < 0.001 16.00 (11.50 to 20.00) 55% 0.41
-Vitality 271 38.68 (17.85) 51.49 (18.68) p < 0.001 15.00 (12.50 to 17.50) 68% 0.67
-General Health 268 50.86 (18.80) 58.39 (19.55) p < 0.001 8.50 (6.00 to 10.00) 65% 0.44
SF-36 Health Change (1–5**) 272 3.23 (1.08) 2.15 (1.09) p < 0.001 1.50 (1.00 to 1.50) 69% 0.68
SF-36 Physical Component 263 43.13 (10.25) 47.10 (9.78) p < 0.001 3.90 (2.83 to 4.97) 68% 0.44
SF-36 Mental Component 263 38.31 (11.67) 45.01 (11.76) p < 0.001 6.45 (4.94 to 7.96) 69% 0.55
KINDL subscales (0–100)
-Psychic 35 67,36 (15,27) 70,68 (15,64) p = 0.188 3.41 (-2.27 to 9.09) 60% 0.20
-Somatic 35 70,57 (14,47) 75,60 (9,35) p = 0.071 4.17 (0.00 to 9.72) 66% 0.37
-Social 35 69,90 (11,95) 73,16 (11,78) p = 0.063 4.17 (0.00 to 7.29) 66% 0.28
-Function 33 64,39 (14,33) 67,94 (10,44) p = 0.187 3.41 (-2.27 to 7.96) 61% 0.25
KINDL Summary Score (0–100) 35 67.86 (11.02) 71.48 (9.79) p = 0.063 3.59 (-0.07 to 7.65) 63% 0.34
KITA subscales (0–100)
-Psychosoma 51 69.53 (15.45) 77.21 (13.60) p = 0.001 9.38 (4.17 to 12.50) 69% 0.51
-Daily Life 56  59.23 (21.78)  68.14 (18.52) p = 0.001 10.42 (4.17 to 14.58)  63%  0.53
*Positive differences indicate improvement. Improved: Percentage of patients improved from baseline. **1 = "much better now than one year ago", 
5 = "much worse now than one year ago". SRM: Standardised Response Mean effect size (small: 0.20–0.49, medium: 0.50–0.79, large: ≥ 0.80).BMC Public Health 2007, 7:61 http://www.biomedcentral.com/1471-2458/7/61
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Since, however, EYT was evaluated as a therapy package,
the question of specific therapy effects vs. non-specific
effects (placebo effects, context effects, patient expecta-
tions etc.) was not an issue of the present analysis.
Since EYT was to be evaluated under routine conditions,
therapy was administered at the discretion of the physi-
cians and EYT therapists, and not according to a standard-
ised protocol. This raises the question of whether study
interventions would be replicable in future studies. How-
ever, EYT therapists worldwide are trained according to a
highly standardised curriculum, specifying individual EYT
movements for specific diseases, constitution types, and
movement patterns. Therefore, relevant therapy differ-
ences across settings would not be expected. Moreover, in
this study, any local therapy differences would probably
be offset by the large number of participating EYT thera-
pists. Nevertheless, a limitation of our study is that the
specific EYT movements selected for each patient were not
documented.
Study implications
This study confirms previous studies of the characteristics
of AM users [15,35-38]: Patients are predominantly mid-
dle-aged women or children, education and occupation
levels are higher than average, and typical indications are
mental and musculoskeletal disorders. Previous studies
conducted in inpatient [16-24] and outpatient clinics
[24,25] have evaluated AM therapy including EYT for
rheumatoid arthritis [16], asthma [24], hepatitis C
[17,25], breast cancer [18], anorexia nervosa [19], lumbar
disc disease [20], chronic musculoskeletal pain [21], and
in the rehabilitation after stroke [22] and myocardial inf-
arction [23]. All these studies had some favourable out-
comes; the three largest studies (range 60–81 AM
patients) found improved quality of life in breast cancer
patients [18]; high anorexia nervosa cure rates [19]; and
reduced pain, reduced use of non-steroidal anti-inflam-
matory drugs and muscle relaxants, and earlier return to
work in lumbar disc disease [20].
In accordance with these findings from secondary care,
our predominantly primary care study of EYT users dem-
onstrated long-standing improvements in disease symp-
toms and quality of life across a range of conditions. Most
common indications for EYT were musculoskeletal pain,
depression, fatigue, childhood emotional disorder, and
headache disorders. For these conditions some patients
will not profit from standard therapies (drugs, physiother-
apy, psychotherapy, multimodal inpatient therapies, sur-
gery), e.g. between three and five patients must be treated
with drugs for one patient to benefit [39-42]. Other
Disease and Symptom Scores Figure 2
Disease and Symptom Scores. Disease Score: physicians' assessment, Symptom Score: patients' assessment. Range 0 "not 
present", 10 "worst possible".
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patients discontinue standard therapies due to adverse
reactions or reject them because therapies are passive (e.g.
drugs, passive physiotherapy) or can be felt as intrusive,
too verbal (psychotherapy) or too mechanical-repetitive
(exercise physiotherapy). Thus, for patients where stand-
ard therapies are not preferred or tolerated well, or do not
cure, EYT as a non-verbal artistic exercising therapy is a
promising treatment option.
Conclusion
In this study, patients practising EYT exercises had long-
term reduction of chronic disease symptoms and
improvement of quality of life, without relevant increase
KITA Psychosoma and Daily Life subscales Figure 4
KITA Psychosoma and Daily Life subscales. Range 0–100, higher scores indicate better health. Children aged 1–7 years.
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SF-36 Physical and Mental Component Summary Measures Figure 3
SF-36 Physical and Mental Component Summary Measures. Higher scores indicate better health. Adult patients and 
German population (standardised for age and gender) [28]
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in health service use. Although the pre-post design of the
present study does not allow for conclusions about com-
parative effectiveness, study findings suggest that EYT can
be useful for patients motivated for this therapy.
Abbreviations
AM: anthroposophic medicine, AMOS: Anthroposophic
Medicine Outcomes Study, EYT: eurythmy therapy, IQR:
interquartile range.
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